

Filip Janku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6282807/publications.pdf>

Version: 2024-02-01

152
papers

12,577
citations

34105

52
h-index

29157

104
g-index

156
all docs

156
docs citations

156
times ranked

19425
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	1.9	1
2	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH1</i> -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100197.	3.0	10
3	Clinical characteristics and outcomes of phase I cancer patients with <i>CCNE1</i> amplification: MD Anderson experiences. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
4	First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 1001-1010.	2.6	14
5	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	3.0	15
6	Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 96-106.	7.0	59
7	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	3.4	7
8	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> -mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	4.1	6
9	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor- ⁺ positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	7.0	5
10	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th,) Tj ETQq0 0 0rgBT /Over	4.4	3
11	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. <i>Scientific Reports</i> , 2021, 11, 3667.	3.3	20
12	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with <i>IDH1</i> -Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733.	7.0	33
13	Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , 2021, 11, 5847.	3.3	24
14	First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. <i>Investigational New Drugs</i> , 2021, 39, 1348-1356.	2.6	22
15	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2021, 39, 1357-1365.	2.6	5
16	Vorasidenib, a Dual Inhibitor of Mutant <i>IDH1/2</i> , in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	7.0	112
17	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. <i>Cancers</i> , 2021, 13, 3600.	3.7	37
18	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Hormonal modulation of ESR1 mutant metastasis. <i>Oncogene</i> , 2021, 40, 997-1011.	5.9	22
20	A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA. <i>Scientific Reports</i> , 2021, 11, 19653.	3.3	7
21	Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with <i>RAS/RAF</i> Alterations. <i>Oncologist</i> , 2020, 25, e160-e169.	3.7	55
22	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	7.0	16
23	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	1.6	61
24	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
25	Ivosidenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	1.6	167
26	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	7.0	50
27	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1693-1701.	1.6	86
28	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.	7.0	61
29	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	3.3	10
30	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
31	RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. <i>Journal of Cancer</i> , 2020, 11, 3543-3550.	2.5	8
32	Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2504-2504.	1.6	4
33	The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3547.	1.6	6
34	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3590-3590.	1.6	12
35	Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3640-3640.	1.6	8
36	Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15223-e15223.	1.6	0

#	ARTICLE	IF	CITATIONS
37	A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3162-TPS3162.	1.6	3
38	An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.. Journal of Clinical Oncology, 2020, 38, 6085-6085.	1.6	0
39	Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring <i>NOTCH1</i> loss of function (LOF) mutations.. Journal of Clinical Oncology, 2020, 38, TPS6590-TPS6590.	1.6	5
40	Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy.. Journal of Clinical Oncology, 2020, 38, 3533-3533.	1.6	0
41	Incorporating Circulating Biomarkers into Clinical Trials. , 2020, , 233-247.		0
42	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist, 2019, 24, 219-228.	3.7	30
43	Liquid Biopsies Using Plasma Exosomal Nucleic Acids. Oncoscience, 2019, 6, 296-297.	2.2	1
44	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720.	8.1	161
45	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell, 2019, 35, 738-751.e9.	16.8	178
46	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	4.1	26
47	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10.	3.0	6
48	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Journal of Hematology and Oncology, 2019, 12, 145.	17.0	35
49	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472.	4.1	10
50	Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors. , 2019, , .		2
51	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3014-3014.	1.6	50
52	Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291.	27.6	762
53	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery, 2018, 8, 184-195.	9.4	283
54	Advances on the BRAF Front in Colorectal Cancer. Cancer Discovery, 2018, 8, 389-391.	9.4	7

#	ARTICLE	IF	CITATIONS
55	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	7.0	127
56	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 671-676.	4.1	33
57	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	2.6	149
58	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	17
59	Phosphatidylinositol 3-Kinase Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	1.6	298
60	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-19.	3.0	2
61	Moving Precision Oncology Forward Amid Myths and Misconceptions. <i>JAMA Oncology</i> , 2018, 4, 1788.	7.1	2
62	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 407-418.	2.3	46
63	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309.	3.7	46
64	Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2002-2002.	1.6	25
65	Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.	1.8	9
66	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	7.0	53
67	Circulating tumor DNA From bench to bedside. <i>Current Problems in Cancer</i> , 2017, 41, 212-221.	2.0	2
68	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509.	7.1	154
69	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	7.0	50
70	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 93-101.	7.7	191
71	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	3.3	21
72	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114

#	ARTICLE	IF	CITATIONS
73	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017, 8, 39254-39267.	1.8	62
74	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017, 2017, 1-18.	3.0	107
75	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. <i>Oncoscience</i> , 2017, 4, 47-56.	2.2	21
76	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017, 8, 33796-33806.	1.8	5
77	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. <i>Oncoscience</i> , 2016, 3, 164-172.	2.2	34
78	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.	3.3	12
79	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016, 5, 3437-3444.	2.8	20
80	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016, 76, 3690-3701.	0.9	203
81	Genomically Driven Tumors and Actionability across Histologies: <i>BRAF</i> -Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 533-547.	4.1	63
82	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	1.6	149
83	Bringing Blood-Based Molecular Testing to the Clinic. <i>Clinical Cancer Research</i> , 2016, 22, 5400-5402.	7.0	8
84	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	4.1	73
85	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	9.4	192
86	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	4.1	78
87	Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, e34-e37.	1.6	12
88	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
89	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	1.8	44
90	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 58.	17.0	191

#	ARTICLE	IF	CITATIONS
91	The mu opioid receptor: A new target for cancer therapy?. <i>Cancer</i> , 2015, 121, 2681-2688.	4.1	63
92	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	1.8	86
93	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1631-1644.	3.1	53
94	A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 730-738.	7.0	265
95	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 215-224.	2.6	8
96	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 177-186.	2.6	25
97	Cell-free DNA as a novel marker in cancer therapy. <i>Biomarkers in Medicine</i> , 2015, 9, 703-712.	1.4	13
98	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015, 33, 700-709.	2.6	12
99	Targeted therapies for advanced Ewing sarcoma family of tumors. <i>Cancer Treatment Reviews</i> , 2015, 41, 391-400.	7.7	23
100	Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 45.	0.8	4
101	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2753-2762.	1.6	372
102	Multiple gene aberrations and breast cancer: lessons from super-responders. <i>BMC Cancer</i> , 2015, 15, 442.	2.6	11
103	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4032-4038.	1.6	583
104	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	9.4	115
105	Challenges and perspective of drug repurposing strategies in early phase clinical trials. <i>Oncoscience</i> , 2015, 2, 576-580.	2.2	42
106	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	1.8	45
107	Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. <i>PLoS ONE</i> , 2014, 9, e93676.	2.5	32
108	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. <i>Oncotarget</i> , 2014, 5, 3012-3022.	1.8	82

#	ARTICLE	IF	CITATIONS
109	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	12.4	285
110	Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. <i>Cell Reports</i> , 2014, 6, 377-387.	6.4	210
111	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, 142, 164-175.		648
112	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. <i>Clinical Cancer Research</i> , 2014, 20, 4827-4836.	7.0	186
113	Erdheim-Chester Disease: Characteristics and Management. <i>Mayo Clinic Proceedings</i> , 2014, 89, 985-996.	3.0	75
114	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. <i>PLoS ONE</i> , 2014, 9, e89388.	2.5	50
115	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. <i>Oncoscience</i> , 2014, 1, 522-530.	2.2	7
116	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. <i>Oncotarget</i> , 2014, 5, 2349-2354.	1.8	54
117	<i>BRAF</i> V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. <i>Oncotarget</i> , 2014, 5, 3607-3610.	1.8	63
118	Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014, 5, 3871-3879.	1.8	11
119	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014, 5, 8937-8946.	1.8	6
120	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014, 5, 11168-11179.	1.8	53
121	Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. <i>Targeted Oncology</i> , 2013, 8, 183-188.	3.6	6
122	<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.	0.9	262
123	Bringing target-matched PI3K from the bench to the clinic. <i>Cell Cycle</i> , 2013, 12, 1817-1818.	2.6	6
124	A Tale of Two Histiocytic Disorders. <i>Oncologist</i> , 2013, 18, 2-4.	3.7	11
125	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.	4.1	42
126	Non-Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment. <i>Journal of Thoracic Oncology</i> , 2013, 8, e19-e20.	1.1	29

#	ARTICLE	IF	CITATIONS
127	Abstract 3514: A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the PI3K/AKT/mTOR pathway.. , 2013, , .		1
128	Germline <i>PTPRD</i> Mutations in Ewing Sarcoma: Biologic and Clinical Implications. <i>Oncotarget</i> , 2013, 4, 884-889.	1.8	24
129	Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. <i>Oncotarget</i> , 2013, 4, 772-784.	1.8	16
130	A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal. <i>Oncotarget</i> , 2013, 4, 463-473.	1.8	27
131	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. <i>Oncotarget</i> , 2013, 4, 705-714.	1.8	96
132	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	7.0	458
133	Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity?. <i>Journal of Clinical Oncology</i> , 2012, 30, 892-893.	1.6	2
134	Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009. <i>Clinical Cancer Research</i> , 2012, 18, 6356-6363.	7.0	21
135	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.	1.6	414
136	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	4.1	88
137	PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10510-10510.	1.6	8
138	KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. <i>PLoS ONE</i> , 2012, 7, e38033.	2.5	44
139	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.	1.8	79
140	Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated in a Phase I Clinic. <i>Oncologist</i> , 2011, 16, 327-335.	3.7	8
141	Autophagy as a target for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 528-539.	27.6	709
142	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.	2.5	174
143	BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes. <i>PLoS ONE</i> , 2011, 6, e25806.	2.5	83
144	Novel Therapeutic Targets in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1601-1612.	1.1	127

#	ARTICLE	IF	CITATIONS
145	<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.	4.1	311
146	Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement. <i>Irish Journal of Medical Science</i> , 2011, 180, 765-766.	1.5	4
147	A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temozolomide in Patients with Advanced Gynecologic and Breast Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 6840-6846.	7.0	47
148	Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. <i>Journal of Clinical Oncology</i> , 2010, 28, e633-e636.	1.6	77
149	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 4031-4037.	7.0	15
150	Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 401-414.	27.6	231
151	KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. <i>Melanoma Research</i> , 2005, 15, 251-256.	1.2	38
152	4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. <i>Bulletin Du Cancer</i> , 2004, 91, E279-83.	1.6	5